Characterization of Spinal Actions of Ten Substance P Analogs
On the basis of data obtained in smooth muscles  it was assumed that substance P (SP) analogues containing D-amino acids will antagonise the spinal actions of tachykinins. It was however rapidly realised that SP antagonists exert direct effects on the rat spinal cord. In fact, undeca or C-terminal octapeptide analogues of SP containing D-Trp in positions 7 and 9 or 7,9 and 10 cause an initial increase of the blood pressure followed by a long lasting fall to levels below 80 mmHg within 20–30 min when applied intrathecally (i.th.). In a number of experiments, the hypotension was large enough to cause death of the animal [2, 3, 4].
KeywordsHeart Rate Mean Arterial Blood Pressure Cardiovascular Response Spinal Cord Level Spinal Action
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Regoli D, Escher E, Drapeau G, D’Orléans- Juste P, Mizrahi J (1984) Receptors for substance P. III. Classification by competitive antagonists. Eur J Pharmacol 97: 179–189.PubMedCrossRefGoogle Scholar
Loewy AD, Sawyer WB (1982) Substance P antagonist inhibits vasomotor responses elicited from ventral medulla in rat. Brain Research 245: 379–383.PubMedCrossRefGoogle Scholar
Yashpal K, Gauthier SG, Henry JL (1985) Substance P given intratheca11y at the spinal T9 level increases adrenal output of adrenaline and noradrenaline in the rat. Neuroscience 15 (2): 529–536.PubMedCrossRefGoogle Scholar
Takano Y, Sawyer WB, Loewy AD (1985) Substance P mechanisms of the spinal cord related to vasomotor tone in the spontaneously hypertensive rat. Brain Res 334: 105–116.PubMedCrossRefGoogle Scholar
Regoli D, Escher E, Mizrahi J (1984) Substance P: structure-activity studies and the development of antagonists. Pharmacology 28: 301–320.PubMedCrossRefGoogle Scholar
Escher E, d’Orléans-Juste P, Dion S, Drapeau G, Mizrahi J, Regoli D (1984) A substance P antagonist not containing D-Tryptophane. Eur J Pharmacol 105; 375–377.PubMedCrossRefGoogle Scholar
© Springer-Verlag New York Inc. 1987